Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

4.450 +0.020 (+0.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Insiders Selling DocuSign, Adobe And 2 Other Stocks
The Nasdaq settled higher by 2% on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
Why Shares of Myriad Genetics Dropped 24% This Week
The genetic-testing company announced an acquisition and lowered its guidance. 
Via The Motley Fool
Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook
Via Benzinga
Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation
Via Benzinga
Recap: Myriad Genetics Q1 Earnings
Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 70 points on Tuesday. 
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads. 
Via Benzinga
Dow Drops Over 200 Points; Crude Oil Rises Sharply
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 85 stocks hit new 52-week lows. 
Via Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Myriad Genetics: Q3 Earnings Insights
Myriad Genetics (NASDAQ:MYGN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 09:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Preview: Myriad Genetics
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that Myriad... 
Via Benzinga
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform
Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments. 
Via Benzinga
Can Artificial Intelligence Predict Our Future Health?
Thousands of financial investors and Wall Street pundits advise people daily about what economic trends are coming, what stocks are hot and what is on the upswing. Those same investors and banks... 
Via Benzinga
40 Stocks Moving In Tuesday's Mid-Day Session
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare... 
Via Benzinga
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
Upgrades 
Via Benzinga
Myriad Genetics's Earnings: A Preview
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Myriad... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was... 
Via Benzinga
77 Biggest Movers From Yesterday
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate... 
Via Benzinga
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-... 
Via Benzinga
Myriad Genetics, Inc (MYGN) Q3 2021 Earnings Call Transcript
MYGN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.